Evenity (Romosozumab) Cost in Nebraska 2026: Prices, Insurance, and Savings
Romosozumab, sold under the brand name Evenity by Amgen and UCB, is a monoclonal antibody that inhibits sclerostin. It is given as a 210 mg subcutaneous injection once monthly, for a maximum of 12 doses over a patient's lifetime, and it carries an FDA boxed warning for cardiovascular risk (myocardial infarction and stroke). The FDA-approved indication is osteoporosis treatment in postmenopausal women at high risk of fracture. There is no generic or biosimilar version on the U.S. market as of this review.
The real cost question for a Nebraska patient is rarely "what is the list price." It is closer to: who actually pays the list price, and who pays close to zero. Between manufacturer copay assistance, insurance denials, and Medicaid formulary exclusions, the same drug can cost a patient anywhere from $0 to over $20,000 a year depending entirely on coverage status, not on anything specific to Nebraska geography.
Romosozumab (Evenity) is an FDA-approved injectable osteoporosis treatment for postmenopausal women at high fracture risk, limited to a 12-month course under its label. It has no generic equivalent, and its manufacturer-reported list price has historically been reported in the range of roughly $1,800 per monthly dose, though this figure moves with manufacturer pricing changes and was not independently re-verified against a current pricing source for this review (last checked May 2026). Whether a Nebraska patient pays anywhere near that amount depends on insurance type, prior authorization outcomes, and eligibility for manufacturer assistance, not on the sticker price itself.
What the price actually is, and what needs verification
Public reporting has placed Evenity's list (wholesale acquisition) price at roughly $1,800 to $1,900 per monthly injection, which would put a full 12-dose course in the neighborhood of $20,000 to $22,000. These figures come from prior published pricing summaries rather than a Nebraska-specific pharmacy survey, and drug list prices change at least annually. Before treating any specific number as current, confirm it against Amgen's own pricing information or a pharmacy benefit quote, since this article cannot verify a live 2026 price for Nebraska specifically.
For comparison and clinical context, romosozumab is priced well above generic oral bisphosphonates (commonly a few dollars to around $15 a month) and in a similar range to other injectable bone-building agents. That relative ranking is stable even when exact dollar figures shift.
Does Nebraska Medicaid cover Evenity?
Several state Medicaid programs have historically excluded or heavily restricted romosozumab from preferred drug lists because of its cost relative to other osteoporosis therapies. Whether Nebraska Medicaid (including Heritage Health managed care plans) currently covers Evenity, and under what prior authorization criteria, could not be independently confirmed for this review. Medicaid formularies are reviewed and updated on a recurring basis, so this is exactly the type of fact that needs a direct check rather than a one-time citation.
If you or a patient you are advising is on Nebraska Medicaid, the reliable path is to call the plan's pharmacy benefits line or check the current preferred drug list directly, and to ask specifically whether a prior authorization exception process exists for patients who have failed or cannot tolerate bisphosphonates. Nebraska Medicaid's fair hearing process is a general administrative right available for coverage denials, but success in a specific case depends on documentation this article cannot predict.
Commercial insurance: what is likely true, and what to confirm
Most commercial insurers that operate specialty pharmacy formularies require prior authorization for high-cost bone anabolic agents like romosozumab. Typical prior authorization criteria for this drug class generally include a confirmed osteoporosis diagnosis (by bone density T-score or fragility fracture history) and documentation of an inadequate response to, or intolerance of, a bisphosphonate. Whether a specific Nebraska plan (Blue Cross Blue Shield of Nebraska, UnitedHealthcare, Aetna, Medica, or others) applies exactly these criteria, and what the specialty-tier copay is, varies by plan year and by the individual's specific plan design. Do not assume a specific insurer's rules without checking the current plan document or calling member services, since formulary tiers and copay structures change annually.
The FDA label's boxed warning for cardiovascular risk is a real, stable fact that insurers commonly reference when requesting additional clinical documentation before approving coverage. That warning reflects a finding from the drug's pivotal trial program; the exact numeric event rates reported in that trial should be confirmed against the primary publication or the FDA label rather than repeated from secondary summaries.
The manufacturer savings card: mechanics that are relatively stable
Amgen and UCB have offered a copay savings card for Evenity aimed at commercially insured patients, intended to reduce out-of-pocket cost per dose. The general mechanics of manufacturer copay cards for specialty biologics are consistent across this drug class:
- They apply only to patients with commercial (private) insurance that already covers the drug.
- They are not usable by patients on Medicare, Medicaid, TRICARE, or other government-funded insurance, due to federal anti-kickback rules governing copay assistance.
- They reduce the patient's copay or coinsurance after the insurance claim is processed; they do not apply to the full cash price for uninsured patients.
- Enrollment is typically done through the prescriber's office or the manufacturer's support program, with activation taking one to a few business days.
The specific maximum dollar benefit per dose, the annual cap, and current program terms change periodically and should be confirmed directly through Amgen's current program materials or by calling the specialty pharmacy dispensing the drug, rather than relying on a fixed number here.
Amgen has also historically operated patient assistance programs for uninsured patients meeting income criteria (commonly referenced against a percentage of the federal poverty level). Current eligibility thresholds and application steps should be confirmed directly with the program, since income cutoffs and enrollment periods can change.
Verification checklist: stable facts vs. facts you must reverify
Reference this information when discussing romosozumab pricing or coverage with a patient. The left column contains data from the FDA label and romosozumab's regulatory status, which remain relatively stable. The right column reflects decisions made by insurance plans, state programs, or individual pharmacies, which may shift periodically.
| Question | Likely stable (check once a year) | Date-sensitive (verify before each decision) |
|---|---|---|
| Is romosozumab FDA-approved and for what population? | Yes, for postmenopausal women at high fracture risk, per FDA label | Not applicable |
| Does it carry a boxed warning? | Yes, cardiovascular risk warning | Not applicable |
| Is there a generic or biosimilar? | No, as of this review | Confirm at time of prescribing, since this can change |
| What is the monthly list price? | Order of magnitude (high-cost specialty biologic) | Exact dollar figure, confirm with manufacturer or pharmacy |
| Does Nebraska Medicaid cover it? | Medicaid coverage of high-cost bone anabolics is often restricted nationally | Nebraska's current preferred drug list and PA criteria, call the plan |
| Does my commercial plan cover it? | Prior authorization is standard for this drug class | Specific plan's tier, copay, and PA criteria, check current plan documents |
| Is a manufacturer savings card available? | Manufacturer copay cards are a standard feature for specialty biologics like this one | Current maximum benefit, annual cap, and eligibility rules, check the live program |
| Can compounding pharmacies legally prepare this biologic? | FDA restricts compounding of biologic products outside the scope of an approved biologics license; this is a general federal rule, not a Nebraska-specific allowance | Any specific pharmacy's legal basis for offering a "compounded" version, this needs individual verification and should be discussed directly with the prescriber |
If a claim would fall in the right-hand column, treat any number you see online (including in this article) as a starting point for a phone call, not as a final answer.
Compounded romosozumab: treat this claim with caution
Romosozumab is a biologic drug regulated as a biologics license application (BLA) product. FDA guidance on mixing, manipulating, or diluting biological products outside the scope of an approved BLA describes significant restrictions on this practice; compounding pharmacies generally cannot obtain a legal bulk source of a patent-protected, BLA-licensed monoclonal antibody the way they can for many small-molecule drugs. Any claim that a Nebraska 503A pharmacy is offering a lower-cost "compounded romosozumab" should be verified directly with that pharmacy's licensing and with the prescriber before a patient relies on it, since the FDA's general position on compounding biologics outside an approved BLA is restrictive rather than permissive. Patients considering any non-FDA-approved version of a biologic drug should understand that potency, sterility, and clinical effect have not been independently verified by the FDA the way they have for the branded product.
Telehealth prescribing
Nebraska allows telehealth encounters for many specialty prescriptions, including injectable osteoporosis medications, provided the prescriber establishes an appropriate provider-patient relationship during the visit. The physical injection still needs to happen somewhere: either in a clinical setting or, per the FDA label, by a trained individual after appropriate instruction. Many prescribers choose to administer the first several doses in-office to monitor for injection-site reactions and other early effects before moving to home administration, which is a matter of clinical judgment rather than a fixed rule.
How romosozumab compares to other osteoporosis options on cost
| Option | Typical cost pattern | Coverage pattern | Key trade-off |
|---|---|---|---|
| Generic bisphosphonates (alendronate, risedronate) | Low, often single-digit to low double-digit dollars per month | Broadly covered, including by most Medicaid programs | Slower bone density gains; well-established long-term safety data |
| Zoledronic acid (annual IV infusion) | Moderate per-infusion cost at an infusion center | Generally covered by Medicare Part B and commercial plans | Requires an annual infusion visit |
| Denosumab (Prolia) | High, billed every six months | Often covered by Medicare Part B and commercial plans, sometimes Medicaid with prior authorization | Discontinuation without a follow-up antiresorptive is associated with a rebound vertebral fracture risk described in the literature; confirm current guidance with a specialist |
| Teriparatide / abaloparatide (daily injections) | High, monthly cost among the more expensive anabolic options | Coverage varies, often requires prior authorization | Daily self-injection burden; time-limited course |
| Romosozumab (Evenity) | High, but limited to a fixed 12-month course | Coverage typically requires prior authorization and bisphosphonate failure documentation; Medicaid coverage uncertain in many states | Fastest reported bone density gains among approved agents, but carries a cardiovascular boxed warning |
Exact percentages for fracture reduction or bone density change from each drug's pivotal trial (ARCH, FRAME, HORIZON, VERO, and similar studies) are widely cited in secondary sources, but the specific numbers should be confirmed against the primary trial publication or the FDA label before being repeated as precise figures. This review could not verify a specific citation for those numbers with confidence and is flagging that as a gap rather than presenting an unconfirmed statistic as settled fact.
Practical steps to lower cost, regardless of exact pricing
- Ask about the manufacturer savings card first if you have commercial insurance and the drug is covered. This is generally the most effective lever for eligible patients.
- Ask the prescriber's office to run a formal benefits investigation before the first fill, so prior authorization and copay amount are known ahead of time rather than discovered at the pharmacy counter.
- Ask about patient assistance programs if uninsured or facing a denial, and get current income eligibility rules directly from the manufacturer's program rather than an outdated web summary.
- Discuss sequencing with the prescriber. Some clinicians use romosozumab for its fixed 12-month bone-building course and then transition to a lower-cost antiresorptive to maintain gains. Whether this is appropriate for a given patient is a clinical decision, not a cost shortcut to apply universally.
- Do not pursue an unverified compounded version as a cost-saving shortcut without discussing the legal and safety uncertainty with the prescriber first.
What is established, what is plausible, and what is not established
Established: Romosozumab is FDA-approved for postmenopausal women at high fracture risk, given as a monthly injection for up to 12 months, with a boxed warning for cardiovascular risk. There is no generic or biosimilar on the market as of this review. Manufacturer copay cards for specialty biologics generally exclude government-insured patients, by federal rule.
Plausible but requiring verification for Nebraska specifically: The exact current list price, the exact Nebraska Medicaid coverage decision, specific commercial insurer copay amounts, and whether any Nebraska compounding pharmacy is legally offering a compounded version.
Not established from the material available for this review: Specific percentage effect sizes from individual clinical trials, a direct quotation from any named clinical authority about prior authorization burden, and a verified statement from a bone health professional society about compounded biologics. These claims could not be traced to a checkable primary source and have been removed rather than repeated as fact.
Frequently asked questions
What does Evenity (romosozumab) cost without insurance?
Does Nebraska Medicaid cover Evenity?
Is compounded romosozumab a legitimate lower-cost option in Nebraska?
Can I get Evenity prescribed through telehealth in Nebraska?
How does the manufacturer savings card work?
References
- U.S. Food and Drug Administration. Drug information. https://www.fda.gov/drugs
This article is a draft prepared for editorial review. Several figures require direct verification against current FDA labeling, Nebraska Medicaid resources, and payer or pharmacy documentation before this page should be treated as a final source of pricing or coverage information.